ClinicalTrials.gg
RecruitingNCT07521800DRAGON-TAVIUpdated Apr 13, 2026

Remote ECG Monitoring Post TAVI

An interventional study of Remote ECG monitoring and Standard Care (in control arm) in TAVI(Transcatheter Aortic Valve Implantation), Remote Monitoring and Arrythmia, sponsored by Medical University of Silesia. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Dec 2023, registered Nov 2025).
  • Started Dec 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The DRAGON TAVI study is a multicenter, prospective, open, randomised trial, which will enrol 250 patients, randomized 1:1 to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and standard care (ie. control group, which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days). The duration of the study is 12 months ± 1 month.

02

Conditions studied

  • TAVI(Transcatheter Aortic Valve Implantation)
  • Remote Monitoring
  • Arrythmia
  • Atrial Fibrillation (AF)
  • Atrioventricular Block

Keywords

  • TAVI
  • ECG
  • Monitoring
03

In context

Arrhythmias, Cardiac

1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

This study's planned enrollment of 250 is above the median of 100 across 517 interventional studies indexed under Arrhythmias, Cardiac.

Browse Arrhythmias, Cardiac studies →

Lead sponsor

Medical University of Silesia is the lead sponsor of 115 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient age over 18 years old
  • Severe aortic stenosis
  • Moderate or high cardiovascular risk based on current ESC Guidelines "Heart Team" qualification for TAVI
  • Written of the patient for participation in the study

Exclusion criteria

Exclusion Criteria:

  • History of atrial fibrillation or atrial flutter
  • Previously known conduction disturbances**
  • Presence of: pacemaker, CRT-P, ICD, CRT-D before or after TAVI
  • Ischaemic stroke, , MI or heart surgery within 1 month before TAVI qualification
  • Haemorrhagic stroke within 1 year before TAVI qualification
  • Chronic therapy
  • Comorbidities (e.g. drug addiction, alcohol abuse, emotional/mental disorders) which do not allow safe participation in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Remote ECG monitoring

    Device: continuous 30-day ECG monitoring with visits triggered by ECG findings

    Device: Remote ECG monitoring

  • Active comparator
    Standard care

    Control group, which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days

    Device: Standard Care (in control arm)

Interventions

  • DeviceRemote ECG monitoring

    Patients will be randomized to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and the control group (which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days).

  • DeviceStandard Care (in control arm)

    Description: Patients will be randomized to the study group (continuous 30-day ECG monitoring with visits triggered by ECG findings) and the control group (which will receive the standard post op 24-48h ECG monitoring and a regular follow-up visit with standard ECG within 30 days).

06

What researchers measure

Primary outcomes

  1. The first primary endpoint will be the assessment of the total incidence of clinically significant atrio-ventricular block.

    Time frame: 30 days

Secondary outcomes

  1. Secondary endpoints will include: All-cause mortality; Major composite adverse cardiovascular events (MACEs, ie, cardiovascular death, stroke, myocardial infarction, hospitalisation for heart failure); Episodes of syncope; cardiac arrhythmias

    Time frame: 24 months

07

Study locations

3 of 4 sites recruiting
  • Division of Cardiology, Departement of Medical Science University of Turin, Città della Salute e Della Scienza
    Turin, Italy
    Recruiting
    • Fabrizio D'Ascenzo, Professor of Medicine · Contact
  • Department of Invasive Cardiology, Medical University of Białystok, Bialystok, Poland
    Bialystok, Poland
    Recruiting
  • Medical University of Silesia
    Katowice, 40-055, Poland
    Recruiting
  • Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
    Katowice, 40-635, Poland
    Not yet recruiting
    • Wojciech Wańha, MD, PhD · Contactwojciech.wanha@gmail.com · 0048504827636
    • Wojciech Wańha, PhD · Principal investigator
    • Wojciech Wojakowski, Prof. · Principal investigator
    • Grzegorz Smolka, Prof. · Principal investigator
    • Krystian Wita, Prof. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07521800
Responsible party
Wojciech Wańha (MD, PhD, Prof., Medical University of Silesia) — Principal investigator
First posted
Apr 13, 2026
Start date
Dec 1, 2023
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Apr 13, 2026

Study contacts

Wojciech Wańha, MD, PhD
Contact
wojciech.wanha@gmail.com
504827636

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion